How do you counsel patients on JAK inhibitors about the risk of venous thromboembolism, MACE, and cancer?

I advise patients that there remain many unanswered questions regarding these side effects that will be resolved with longer term use with these agents. Shared decision-making is critical for these discussions. Data available from current extensions of clinical trials for JAKi, additional risk facto...